Resistance to Proteasome Inhibitors in Cancer : Molecular Mechanisms and Strategies to Overcome Resistance /
| Autor Corporativo: | |
|---|---|
| Otros Autores: | |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
Cham :
Springer International Publishing : Imprint: Springer,
2014.
|
| Edición: | 1st ed. 2014. |
| Colección: | Resistance to Targeted Anti-Cancer Therapeutics,
|
| Materias: |
Tabla de Contenidos:
- Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer
- Resistance to proteasome inhibitors in multiple myeloma
- Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma
- Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis
- Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy
- Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition
- Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies
- Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches
- Targeting the proteasome pathway for the treatment of solid tumors
- Oxidative stress and the proteasome: mechanism and the therapeutic relevance
- Proteotoxic stress and proteasome inhibitor efficacy and resistance
- Proteasome inhibitors versus E3 ligase inhibitors for cancer therapy
- Novel ubiquitin E3 ligases as targets for cancer therapy: Focus on breast cancer associated gene 2 (BCA2)
- The 26S proteasomal ATPases: structure, function, regulation and potential for cancer therapies
- Deubiquitinating enzymes as novel targets for cancer therapies.